Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2020-03-16

FDA Approved: AMLODIPINE, VALSARTAN AND HYDROCHLOROTHIAZIDE — Supplemental Application (Lupin Pharmaceuticals, Inc.)

View source ↗

Summary

FDA approved Lupin's supplemental application for a generic fixed-dose combination of amlodipine, valsartan, and hydrochlorothiazide for the treatment of hypert…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • AMLODIPINE, VALSARTAN AND HYDROCHLOROTHIAZIDE (amlodipine/valsartan/hydrochlorothiazide)

Snippet

SUPPL AP for AMLODIPINE, VALSARTAN AND HYDROCHLOROTHIAZIDE (AMLODIPINE, VALSARTAN AND HYDROCHLOROTHIAZIDE)